| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 10.92 | 0.00 (0.00%) | 2.92 - 13.30 | 1.1 million (Below Avg) |
Market data as of 4:00PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 11.21 |
|---|---|
| Previous Close | 10.92 |
| Day's Range | 10.76 - 11.52 |
| Market Cap | 309.5M |
| Avg Volume (10 Day) | 1.9M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.85 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
PR Newswire - Monday 06/17/2013 7:00 PM ET
Positive Findings, Collaborations, and NDA Filings Strengthen Pipelines - Research Report on Clovis Oncology, MannKind, TESARO, Peregrine Pharmaceuticals, and Vanda Pharmaceuticals
PR Newswire - Thursday 06/06/2013 8:00 AM ET
Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
PR Newswire - Wednesday 06/05/2013 9:00 PM ET
Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
PR Newswire - Friday 05/31/2013 4:00 PM ET
Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
PR Newswire - Friday 05/31/2013 6:55 AM ET
Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
PR Newswire - Thursday 05/30/2013 8:30 PM ET
Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
PR Newswire - Thursday 05/23/2013 10:00 PM ET
| VNDA | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 2.33% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 9.75 |
| Company | Last | Change |
|---|---|---|
| XOMA Corp | 3.84 | 0.00% |
| Receptos Inc | 18.01 | -0.72% |
| Cerus Corp | 4.55 | 0.00% |
| Dyax Corp | 3.23 | 0.00% |
| Threshold Pharmaceuticals Inc | 5.50 | 0.00% |
Data is delayed by at least 15 min.